共 50 条
- [21] EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Balar, Arjun VasantMcGregor, Bradley AlexanderRosenberg, Jonathan E.van der Heijden, Michiel SimonPark, Se HoonLee, Jae-LyunHarrison, Michael RogerHeath, Elisabeth, IStein, Mark N.Loriot, YohannNecchi, AndreaSteinberg, Joyce LetaLiang Shang-YingKim, EricTrowbridge, JanetCampbell, Mary S.Petrylak, Daniel PeterYu, Evan Y.
- [22] Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Arance, Ana Mariade la Cruz-Merino, LuisPetrella, Teresa M.Jamal, RahimaNy, LarsCarneiro, AnaBerrocal, AlfonsoMarquez-Rodas, IvanSpreafico, AnnaAtkinson, VictoriaSvedman, Fernanda CostaMant, AndrewSmith, Alan D.Chen, KeDiede, Scott J.Krepler, ClemensLong, Georgina V.
- [23] Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyCLINICAL CANCER RESEARCH, 2021, 27 (02) : 492 - 503Ferrara, RobertoNaigeon, MarieAuclin, EdouardDuchemann, BorisCassard, LydieJouniaux, Jean-MehdiBoselli, LisaGrivel, JonathanDesnoyer, AudeMezquita, LauraTexier, MatthieuCaramella, CarolineHendriks, LizzaPlanchard, DavidRemon, JordiSangaletti, SabinaProto, ClaudiaGarassino, Marina C.Soria, Jean-CharlesMarabelle, AurelienVoisin, Anne-LaureFarhane, SihamBesse, BenjaminChaput, Nathalie
- [24] Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)McGregor, Bradley AlexanderBalar, Arjun VasantRosenberg, Jonathan E.Van der Heijden, Michiel SimonPark, Se HoonLee, Jae-LyunKojima, TakahiroHarrison, Michael RogerHeath, Elisabeth I.Stein, Mark N.Loriot, YohannNecchi, AndreaSteinberg, Joyce LetaLiang, Shang-YingTrowbridge, JanetPetrylak, Daniel P.Yu, Evan Y.
- [25] Neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in patients with potentially resectable NSCLC: An open-label, single-arm, phase II trialANNALS OF ONCOLOGY, 2021, 32 : S942 - S942Zhu, X.Sun, L.Song, N.Sun, F.Yang, J.Duan, L.Zhao, D.He, W.Luo, J.Zhang, H.Wu, C.Zhu, Y.Zhang, P.Jiang, G.
- [26] Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Galsky, Matt D.Bamias, AristotelisArranz Arija, Jose AngelDavis, Ian D.De Santis, MariaKikuchi, Eijidel Muro, Xavier GarciaPark, Se HoonDe Giorgi, UgoAlekseev, BorisMencinger, MarinaIzumi, KoujiPuente, JavierLi Jian-RiMecke, AlmutMariathasan, SanjeevBanchereau, RomainHuang XinhuiLee, Chooi PengGrande, Enrique
- [27] PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for Asian patients with advanced triple-negative breast cancer: a phase III RCTs based meta-analysisFRONTIERS IN ONCOLOGY, 2025, 15Ruan, HuaZou, YubinHuang, LifengZha, WenjuanOuyang, QingqingYang, Ling
- [29] Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial A randomized clinical trial of neoadjuvant therapy for ESCCBMC MEDICINE, 2023, 21 (01)Li, YongZhou, AipingLiu, ShuoyanHe, MingChen, KenengTian, ZiqiangLi, YinQin, JianjunWang, ZhenChen, HaiquanTian, HuiYu, YueQu, WangXue, LiyanHe, ShunWang, ShuhangBie, FenglongBai, GuangyuZhou, BolunYang, ZhaoyangHuang, HuiyaoFang, YanLi, BenjaminDai, XiangrongGao, ShugengHe, Jie
- [30] Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trialBMC CANCER, 2025, 25 (01)Furukawa, JunyaKakei, YasumasaMurakami, SaeKita, HiroshiUeki, HidetoHara, TakutoTeishima, JunHinata, NobuyukiMiyake, HideakiFujisawa, MasatoShirakawa, Toshiro